CRDF Stock Price, Cardiff Oncology, Inc. Quote, Chart

Market Summary

USD4.09+0.10

Market Closed

2.51%

CRDF Stock Price

View Fullscreen

CRDF RSI Chart

CRDF Valuation

Market Cap

182.7M

Price/Earnings (Trailing)

-4.41

Price/Sales (Trailing)

374.45

Price/Free Cashflow

-5.81

CRDF Price/Sales (Trailing)

CRDF Profitability

Operating Margin

100.00%

Return on Equity

-59.42%

Return on Assets

-50.76%

Free Cashflow Yield

-17.22%

CRDF Fundamentals

CRDF Revenue

Revenue (TTM)

488.0K

Rev. Growth (Yr)

133.19%

Rev. Growth (Qtr)

1.42%

CRDF Earnings

Earnings (TTM)

-41.4M

Earnings Growth (Yr)

-7.36%

Earnings Growth (Qtr)

4.05%

Breaking Down CRDF Revenue

Last 7 days

-6.0%

Last 30 days

-28.9%

Last 90 days

174.5%

Trailing 12 Months

170.9%

How does CRDF drawdown profile look like?

CRDF Financial Health

Current Ratio

7.41

CRDF Investor Care

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	411.5K	437.0K	462.5K	488.0K
2022	438.5K	620.5K	1.0M	386.0K
2021	355.0K	383.0K	317.0K	365.5K
2020	266.3K	239.6K	323.9K	366.0K
2019	340.2K	298.2K	261.5K	260.3K
2018	510.5K	520.3K	485.3K	378.3K
2017	356.0K	354.0K	388.4K	505.4K
2016	306.0K	361.0K	392.0K	381.0K
2015	296.0K	289.0K	290.0K	313.0K
2014	251.0K	258.0K	271.0K	280.0K
2013	536.0K	543.0K	375.0K	259.0K
2012	202.6K	164.8K	321.8K	451.0K
2011	0	0	0	257.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cardiff Oncology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2023	pace gary w	bought	41,100	1.37	30,000	-
Nov 10, 2023	pace gary w	bought	22,491	0.98	22,950	-
Nov 25, 2022	erlander mark	bought	14,300	1.43	10,000	chief executive officer
Sep 19, 2022	white lale	bought	24,525	1.635	15,000	-
Sep 16, 2022	armitage james o	bought	20,233	1.5564	13,000	-
Sep 16, 2022	levine james e.	bought	46,710	1.557	30,000	chief financial officer
Sep 15, 2022	tannenbaum renee p	bought	17,168	1.7168	10,000	-
Sep 15, 2022	pace gary w	bought	256,500	1.71	150,000	-
Jul 05, 2022	white lale	acquired	75,030	2.6	28,858	-
Sep 21, 2021	pace gary w	bought	202,500	6.75	30,000	-

Which funds bought or sold CRDF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	unchanged	-	386	534	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	200,000	200,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-21,237	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	66.00	91.00	-%
Apr 24, 2024	Assenagon Asset Management S.A.	new	-	1,350,920	1,350,920	-%
Apr 23, 2024	FIFTH THIRD BANCORP	sold off	-100	-296	-	-%
Apr 22, 2024	PFG Investments, LLC	new	-	53,405	53,405	-%
Apr 22, 2024	America First Investment Advisors, LLC	unchanged	-	15,440	21,360	-%
Apr 18, 2024	DENVER WEALTH MANAGEMENT, INC.	reduced	-39.54	35,387	65,335	0.03%
Apr 15, 2024	Security National Bank	unchanged	-	37,701	52,156	0.01%

Are Funds Buying or Selling CRDF?

Are funds buying CRDF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRDF

No. of Funds

Unveiling Cardiff Oncology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	acorn bioventures, l.p.	4.20%	1,946,762	SC 13G/A
Feb 14, 2023	caxton corp	2.2%	983,607	SC 13G/A
Feb 09, 2023	janus henderson group plc	0.0%	0	SC 13G/A
Jan 26, 2023	acorn bioventures, l.p.	6.38%	3,043,173	SC 13G
Jan 26, 2023	acorn bioventures, l.p.	6.38%	3,043,173	SC 13D/A
Jul 08, 2022	blackrock inc.	1.6%	671,967	SC 13G
Feb 14, 2022	avidity partners management lp	0%	0	SC 13G/A
Feb 14, 2022	corriente advisors, llc	0.0%	0	SC 13G/A
Feb 14, 2022	caxton corp	8.1%	3,479,340	SC 13G/A
Feb 09, 2022	state street corp	1.65%	693,445	SC 13G/A

Recent SEC filings of Cardiff Oncology, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 08, 2024	8-K	Current Report
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Feb 29, 2024	8-K	Current Report

Peers (Alternatives to Cardiff Oncology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Cardiff Oncology, Inc. News

Latest updates

Cardiff Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	1,068,000	1,053,000	940,000	699,000	458,000	253,000	130,000	167,500	70,000	71,000	57,000	119,000	136,000	43,000	68,000	76,870	51,687	69,761	62,021	78,015
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-4.3%	10,488,000	10,961,000	12,316,000	12,135,000	9,520,000	9,086,000	10,534,000	11,148,000	9,659,000	7,084,000	6,957,000	5,514,000	6,616,000	4,499,000	4,145,000	4,192,000	4,381,873	4,259,163	4,258,307	4,023,784	4,181,500
S&GA Expenses	-7.3%	2,725,000	2,939,000	4,296,000	3,083,000	3,078,000	3,077,000	3,086,000	3,940,000	3,835,000	2,930,000	2,838,000	2,235,000	3,417,500	1,644,000	1,669,000	1,486,000	1,517,400	1,440,339	1,427,967	1,375,185	1,684,535
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	232
Income Taxes	-	-	-	1,000	-	1,000	-	-	1,000	-	-	-	1,000	-	-	-	1,000	-	-	-	800	-
Net Income	4.0%	-9,337,000	-9,731,000	-11,150,000	-11,223,000	-8,697,000	-8,571,000	-10,443,000	-10,993,000	-9,442,000	-6,913,000	-6,757,000	-5,179,000	-6,597,000	-4,497,000	-4,124,000	-4,089,000	-4,242,536	-4,141,549	-4,125,303	-3,904,771	-4,158,478
Net Income Margin	3.7%	-84.92	-88.22	-102	-100	-100	-39.12	-60.90	-77.78	-77.40	-80.27	-60.13	-57.46	-	-	-	-	-	-	-	-	-
Free Cashflow	13.6%	-7,147,000	-8,272,000	-7,383,000	-8,667,000	-9,465,000	-7,934,000	-7,007,000	-10,420,000	-7,497,000	-5,563,000	-4,301,000	-5,884,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.7%	82.00	88.00	97.00	107	116	124	131	139	150	141	144	130	135	39.00	30.00	12.00	13.00	12.00	14.00	15.00	14.00
Current Assets	-7.7%	77.00	84.00	93.00	102	111	120	127	136	146	138	143	129	133	38.00	29.00	10.00	11.00	10.00	12.00	12.00	13.00
Cash Equivalents	42.2%	22.00	15.00	19.00	15.00	16.00	19.00	21.00	20.00	12.00	13.00	11.00	15.00	131	36.00	28.00	9.00	10.00	9.00	11.00	11.00	11.00
Net PPE	-6.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	1.00
Liabilities	12.0%	12.00	11.00	11.00	10.00	10.00	10.00	11.00	9.00	9.00	8.00	5.00	5.00	7.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	4.00
Current Liabilities	15.8%	10.00	9.00	9.00	8.00	8.00	8.00	8.00	7.00	7.00	5.00	5.00	4.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00
Shareholder's Equity	-10.4%	70.00	78.00	87.00	97.00	106	113	120	130	140	134	139	125	128	34.00	24.00	6.00	7.00	7.00	9.00	10.00	10.00
Retained Earnings	-2.8%	-339	-330	-320	-309	-298	-289	-281	-270	-259	-250	-243	-236	-231	-224	-220	-212	-208	-204	-200	-196	-192
Additional Paid-In Capital	0.2%	409	408	407	406	405	404	403	402	401	385	384	363	362	261	248	220	217	212	211	208	202
Shares Outstanding	0%	45.00	45.00	45.00	45.00	45.00	43.00	43.00	43.00	42.00	39.00	38.00	37.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	64.00	-	-	-	94.00	-	-	-	259	-	-	-	104	-	-	-	14.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.3%	-7,139	-7,957	-7,132	-8,659	-9,390	-7,486	-6,695	-10,249	-7,390	-5,465	-4,301	-5,884	-5,124	-3,526	-4,291	-3,374	-3,276	-3,187	-3,443	-3,360	-3,612
Share Based Compensation	-4.8%	909	955	1,581	1,064	1,012	1,037	1,055	1,152	990	940	1,036	268	944	362	282	177	270	266	149	200	269
Cashflow From Investing	254.9%	13,561	3,821	11,484	7,329	7,020	5,163	7,608	18,358	-8,794	8,049	-19,005	-111,698	-57.00	-154	-	-	-	-62.35	-	-5.27	-
Cashflow From Financing	-	-	-	-	-	-	75.00	-	-	14,962	-	19,225	1,263	99,757	12,330	22,769	2,456	4,440	1,491	2,904	3,242	-

CRDF Income Statement

2023-12-31

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Royalty revenues	$ 488	$ 386
Costs and expenses:
Research and development	32,857	27,107
Selling, general and administrative	13,043	13,181
Total operating expenses	45,900	40,288
Loss from operations	(45,412)	(39,902)
Other income (expense), net:
Interest income, net	4,069	1,581
Other expense, net	(98)	(383)
Total other income, net	3,971	1,198
Net loss	(41,441)	(38,704)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(24)	(24)
Net loss attributable to common stockholders	$ (41,465)	$ (38,728)
Net loss per common share - basic (in dollars per share)	$ (0.93)	$ (0.89)
Net loss per common share - diluted (in dollars per share)	$ (0.93)	$ (0.89)
Weighted-average shares outstanding - basic (in shares)	44,677	43,600
Weighted-average shares outstanding - diluted (in shares)	44,677	43,600

CRDF Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,655	$ 16,347
Short-term investments	53,168	88,920
Accounts receivable and unbilled receivable	288	771
Prepaid expenses and other current assets	2,301	5,246
Total current assets	77,412	111,284
Property and equipment, net	1,238	1,269
Operating lease right-of-use assets	1,708	2,251
Other assets	1,279	1,387
Total Assets	81,637	116,191
Current liabilities:
Accounts payable	1,966	1,956
Accrued liabilities	7,783	5,177
Operating lease liabilities	691	675
Total current liabilities	10,440	7,808
Operating lease liabilities, net of current portion	1,458	2,040
Total liabilities	11,898	9,848
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,068 and $1,044 at December 31, 2023 and December 31, 2022, respectively; (Note 5)	0	0
Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 shares issued and outstanding at December 31, 2023 and December 31, 2022	4	4
Additional paid-in capital	409,343	404,834
Accumulated other comprehensive loss	(67)	(395)
Accumulated deficit	(339,541)	(298,100)
Total stockholders’ equity	69,739	106,343
Total Liabilities and Stockholders’ Equity	$ 81,637	$ 116,191

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CEO	Dr. Mark Erlander Ph.D.
WEBSITE	cardiffoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Cardiff Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Cardiff Oncology, Inc.? What does CRDF stand for in stocks?

CRDF is the stock ticker symbol of Cardiff Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cardiff Oncology, Inc. (CRDF)?

As of Fri Apr 26 2024, market cap of Cardiff Oncology, Inc. is 182.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRDF stock?

You can check CRDF's fair value in chart for subscribers.

What is the fair value of CRDF stock?

You can check CRDF's fair value in chart for subscribers. The fair value of Cardiff Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cardiff Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRDF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cardiff Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether CRDF is over valued or under valued. Whether Cardiff Oncology, Inc. is cheap or expensive depends on the assumptions which impact Cardiff Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRDF.

What is Cardiff Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CRDF's PE ratio (Price to Earnings) is -4.41 and Price to Sales (PS) ratio is 374.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRDF PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cardiff Oncology, Inc.'s stock?

In the past 10 years, Cardiff Oncology, Inc. has provided -0.371 (multiply by 100 for percentage) rate of return.